Advertisement

Pharmaceutisch Weekblad

, Volume 10, Issue 2, pp 80–85 | Cite as

Formation arid antimicrobial activity of complexes of β-cyclodextrin and some antimycotic imidazole derivatives

  • H. Van Doorne
  • E. H. Bosch
  • C. F. Lerk
Original Articles

Abstract

Complex formation between β-cyclodextrin and six antimycotic imidazole derivatives has been studied. The solubility of all drugs was increased in the presence of β-cyclodextrin. The smallest increase (approx. 5-fold) was observed for miconazol, and the largest increase (approx. 160-fold) was observed for bifonazol. Apparent I:I-complex constants were measured and found to decrease in the order: bifonazol > ketoconazol > tioconazol > miconazol > itraconazol > clotrimazol. The complexes appeared to possess a low, if any, antimicrobial activity. Measurement of inhibition zone sizes, with four test organisms was used to study the release of the antimycotic drugs from topical preparations. The antimycotic drugs were more readily released from topical preparations containing \-cyclodextrin than from the same vehicles without β-cyclodextrin. The rationale of β-cyclodextrin addition to antimycotic topical preparations is discussed.

Keywords

Administration, topical Complexation Cyclodextrin, beta Drag compounding Imidazoles Solubility 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jones SP, Grant DJW, Hadgraft J, Parr JD, Graham D. Cyclodextrins in the pharmaceutical sciences. Part I. Preparation, structure and properties of cyclodextrins and cyclodextrin inclusion compounds. Acta Pharmacol Technol 1984;30:213–23.Google Scholar
  2. 2.
    Duchêne D, Debrueres B, Vaution C. Improvement of drug stability by cyclodextrin inclusion complexation. STP Pharma 1985;1:37–43.Google Scholar
  3. 3.
    Tokumura T, Tsushima Y, Tashuishi K, Kayano M, Machida Y, Nagai T. Evaluation of bioavailability upon oral administration of cinnarizine β-cyclodextrin inclusion complex to beagle dogs. Chem Pharm Bull 1985;33:2962–7.Google Scholar
  4. 4.
    Szejtli J. Cyclodextrins and their inclusion complexes. Budapest: Akademia Kiado, 1982.Google Scholar
  5. 5.
    Szejtli J. Limits of cyclodextrin application in oral drug preparations. J Incl Phenom 1984;2:487–501.Google Scholar
  6. 6.
    Otagiri M, Fuginiaga T, Sakai A, Uekama K. Effects of β- and ψ-cyclodextrin complexation on release of betamethasone from ointment bases. Chem Pharm Bull 1984;32:2401–5.Google Scholar
  7. 7.
    Anonymous. Flurbiprofen eye-drops with cyclodextrins. Japan Kokai 85.136.516 (via Chemical Abstracts 1984;100:73972).Google Scholar
  8. 8.
    Anonymous. Cyclodextrin formulation of hydrophobic drugs. Eur Patent Appl EP94.157.Google Scholar
  9. 9.
    Szente L, Apostol I, Gerloczy A, Szejtli J. Suppositories containing cyclodextrin complexes. Pharmazie 1985;40:406–7.Google Scholar
  10. 10.
    Nambu N, Kikuchi K, Kikuchi T, Takahashi Y, Ueda H, Nagai T. Influence of inclusion of nonsteroidal antiinflammatory drugs with β-cyclodextrin on the irritation to stomach of rats upon oral administration. Chem Pharm Bull 1978;26:3609–12.Google Scholar
  11. 11.
    Uekama K, Irie T, Sunada M, Otagiri M, Arimatsu Y, Nomura S. Alleviation of prochlorperazine induced primary-irritation of skin by cyclodextrin complexation. Chem Pharm Bull 1982;30:3860–2.Google Scholar
  12. 12.
    Lach JL, Cohen J. Interactions of Pharmaceuticals with Schardinger dextrins. II. Interactions with selected compounds. J Pharm Sci 1974;63:1459–62.Google Scholar
  13. 13.
    Hsuy P, Hedge RP, Birmingham BK, Rhodes CT. Studies of the interaction of β-cyclodextrin with ampicillin, methicillin and phenytoin. Drug Dev Ind Pharm 1984;10:601–11.Google Scholar
  14. 14.
    Andersen FM, Bundgaard H. Inclusion complexation of metronidazole benzoate with β-cyclodextrin and its depression of anhydrate-hydrate transition in aqueous suspensions. Int J Pharm 1984;19:189–97.Google Scholar
  15. 15.
    Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instr 1965;4:117–212.Google Scholar
  16. 16.
    Laboratorium der Nederlandse Apothekers. Formularium der Nederlandse Apothekers. 's-Gravenhage: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, 1986.Google Scholar
  17. 17.
    Brauns U. Eigenschaften lösungsvermittelnder Cyclodextrinether. Kiel: Universität Kiel, 1986. Dissertation.Google Scholar
  18. 18.
    Kavanagh FW. Microbiological diffusion assay. I. Operations studies with Cooper equation. J Pharm Sci 1974;63:1459–62.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1988

Authors and Affiliations

  • H. Van Doorne
    • 1
  • E. H. Bosch
    • 1
  • C. F. Lerk
    • 1
  1. 1.Department of Pharmaceutical TechnologyState University of GroningenAW Groningenthe Netherlands

Personalised recommendations